Akoya Biosciences completes merger with Quanterix; shareholders receive 0.1461 QTRX shares + $0.38 cash per share

Akoya Biosciences, Inc.

Merger closed July 8, 2025; Akoya is now a wholly owned subsidiary of Quanterix (QTRX).
Per share: 0.1461 Quanterix shares plus $0.38 cash; adjustments ensure no more than 19.99% of QTRX shares or $20M cash issued.
All outstanding Akoya RSUs and options converted or cancelled per merger agreement.
Board and executive officers replaced with Quanterix appointees; Akoya common stock delisted from Nasdaq.
Prior credit agreement, ESPP, and equity distribution agreement terminated in connection with merger.

item 1.02 item 2.01 item 3.01 item 3.03 item 5.03 item 5.01 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Akoya Biosciences, Inc.: The bylaws were amended and restated to become the bylaws of the surviving Merger Sub.

Change: bylaw amendment

Exact text from the filing

at the Effective Time, the bylaws of Merger Sub as in effect as of immediately prior to the Effective Time became the Amended and Restated Bylaws of Akoya

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Akoya Biosciences, Inc.: The Certificate of Incorporation was amended and restated pursuant to the Merger Agreement.

Change: charter amendment

Exact text from the filing

at the Effective Time, the Certificate of Incorporation of Akoya was amended and restated in the form of the Amended and Restated Certificate of Incorporation that is filed as Exhibit 3.1 hereto

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001104659-25-066306

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.